Myth

In Celtic myth, Oisín (sometimes Ossian) was the Gælic warrior-bard of the 7th century who sought the land of youth – a magical island off the western coast of Ireland.  Today Oisín Biotechnologies is working to make the myth a reality.

Reality

Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself.  We invite you to see how.

Our First Target - Senescent Cells

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.*

* Baker, Darren J., et al. "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan." Nature 1038.16932 (2016)

Accomplishments to Date & the Future

There are two major challenges to clearing senescent cells using our approach.

• First is to design and create the DNA construct that recognizes that a cell has become senescent, and then destroys it.
• Second is to safely and efficiently deliver this construct into cells throughout the body.

Both goals have been achieved in our pioneering proof of concept experiments in 2016.

We’ve first demonstrated the ability to transduce cells both in vitro (cell culture) and in vivo (in aged mice). Then we showed that p16 positive senescent cells can be killed on demand in both in vitro and in vivo environments. Now we are embarked on experiments that will show improvements in both healthspan and lifespan in model organisms from mice to primates. And then, everything changes.

The Science of SENSOlytics™

Our proprietary technology gives persistently senescent cells a helping hand to “do the right thing."  By providing an exogenous apoptotic gene, which is only transiently expressed in cells that already have the p16 gene active, we can precisely induce the senescent cell to commit suicide. Oisín has shown as much as an 80% reduction in senescent cells in cell culture and significant reductions of senescent cell burden in naturally aged mice.

*SENSOlytics™ is an Oisín proprietary platform technology that enables precise targeting of a senescent cell based on the DNA expression of the cell, not on surface markers or other characteristics that might be shared with normal, undamaged cells.

Keep up with the latest about Oisín

What Gives Oisín an Edge?

Our Chief Science Office, John Lewis, PhD, offers a window into our technology and some of our findings in Berlin, Germany, at Undoing Aging 2018. We invite you to listen to the presentation and get excited about Oisín's present and future!

Interview with Gary Hudson, CEO and CoFounder of Oisín 

Get to know a bit more about Oisín via the latest interview with our CEO, Gary Hudson. In the interview you will read about the progress of our company, current initiatives, and how the science is shaping Oisín into a venture with innumerable opportunities, such as our newly established Oncology Company.

Conference: ICSA

We invite you to read the meeting slides that we presented in Montreal, Canada at the International Cell Senescence Association Conference that took place on July 8-11. This document is titled: "Selective Ablation of Senescent and Malignant Cells Using Apoptotic Gene Therapy" and contains scintillating data from some of our on-going studies.

Click to read PDF Document

Founding Investors

Other Investors

Corporate Headquarters: 

800 5th Avenue, Suite 4100, Seattle, WA 98104

Please complete the form below to receive more Information